Petros Grivas
@PGrivasMDPhD
Followers
18K
Following
47K
Media
1K
Statuses
22K
Oncologist, Professor, clinical/translational research, Genitourinary Cancers, bladder, prostate, testis, Univ of Washington, Fred Hutch; views are mine
Seattle, WA
Joined July 2015
RT @BladderCancerUS: From PubMed at @NLM_NIH: The role of DNA methylation and demethylation in bladder cancer: a focus on therapeutic strat….
0
1
0
Exceptional opportunity! Thanks @BladderCancerUS for supporting innovative research! @BCAN_Research @JoshMeeks @HsiehLab @shilpaonc @UroDocAsh @GavinHa @spsutkaMD @yawnyame @mouwlab @GTumors @karima_oualla @ZakhariaYousef @koshkin85 @arkhaki @SimaPorten @AndreaNecchi @MaxKates.
New funding opportunity! BCAN Continuity Grants provide up to $200K to support bladder cancer research interrupted by federal funding gaps. Apply now:
1
3
15
RT @eaonc: Urothelial cancer is the most common type of #bladdercancer. The EA8192 study is evaluating durvalumab and chemotherapy for pati….
0
1
0
RT @BladderCancerUS: => Please share! @PGrivasMDPhD @montypal @m_e_nielsen @SpiessPhilippe @FaltasLab @zklaassen_md @brian_rini @JoshMeeks….
0
3
0
Fully agree with our leader @HutchPresident such a great example of innovative forward-thinking research focusing on cancer screening! . PS: working with @theNCI think tank on ctDNA-based cancer screening trials representing @eaonc was a great experience with lessons learned!.
A terrific example of how @fredhutch is bringing together leading experts from across disciplines and institutions to improve our understanding emerging cancer screening technologies.
0
0
9
RT @fredhutch: Fred Hutch is leading the Vanguard Study, the first of @theNCI-funded Cancer Screening Research Network, to test multi-cance….
0
5
0
RT @SpiessPhilippe: Early postoperative visits improve outcomes in inguinal lymph node dissection for penile cancer - Fazili - 2025 - BJU I….
0
3
0
RT @SpiessPhilippe: Assessing the Impact of Treatment Timing Protocols in Clinical Trials for Bacillus Calmette-Guérin–unresponsive Non–mus….
0
2
0
RT @uretericbud: Did a RALP for a fellow urology colleague 5 years ago. Today at follow up got this awesome gift: bound volume of @JUrology….
0
3
0
RT @Markuseckstein3: 5/5 🚀 Outcomes: All 12 CAR-T pts in drug-free remission at 3 mo; protein-treated pts needed retreatment despite periph….
0
3
0
RT @Markuseckstein3: 4/5 📉 Plasma cells persisted in all arms, but CAR-T cut CD19⁺CD138⁺ plasmablasts by 59 %. CD3⁺ T cells & CD68⁺ macroph….
0
3
0
RT @Markuseckstein3: 3/5 🔬 Follicular architecture: CAR-T obliterated germinal centres—FDC network gone, TFH absent, Ki-67 low (median scor….
0
3
0
RT @Markuseckstein3: 2/5 🧮 In-node B-cell change (CD20): CAR-T 100 % clearance → OBI –92 % → RTX –86 % → BLI –69 %. Only CAR-T drove CD19/C….
0
3
0
RT @Markuseckstein3: 1/5 📊 24 autoimmune pts (SLE, SSc, RA, IIM): OBI n=4, BLI n=4, RTX n=4, CD19-CAR-T n=12. Inguinal LN biopsies pre-tx &….
0
2
0
RT @Markuseckstein3: Sequential inguinal-LN biopsies in 24 patients with SLE, SSc, RA & IIM reveal that a single infusion of CD19-CAR-T cel….
0
5
0
RT @BrandonLuuMD: Even without diabetes, higher blood sugar predicted erectile dysfunction better than testosterone or age in a new study.….
0
8
0
RT @StephenVLiu: A practical guide on managing toxicities from lorlatinib chronically now @LungCaJournal, developed collaboratively by pati….
0
31
0
RT @nataliagandur: 🌟Therapeutic Targeting of MMR-Deficient Cancers🌟.🖋️ Paul Johannet, Benoit Rousseau, Carol Aghajanian,.@MikeFooteMD @MSKC….
0
15
0
Thanks @VivekSubbiah for your exceptional work in drug development & commitment to equitable access to therapies! I recall your quote “think globally, act locally” @ASCO @IshwariaMD @jrgralow @lynn_schuchter @neerajaiims @montypal @shilpaonc @OncBrothers @OncoAlert @BrainTumorDoc.
⭐️For your Sunday reading: Our @JCOGO_ASCO @ASCO @JCO_ASCO paper reveals precision oncology's harsh reality -life-saving personalized cancer treatments exist but remain out of reach for most patients globally due to policy failures & economic barriers. Time to bridge this gap.
2
8
30